WyndhamHopkinsWilsonMD

Oncology • Bethesda, MD

Physician

Join to view full profile

Dr. Wilson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wilson's full profile

Already have an account?

Office
Room 4n115 Bldg 10
9000 Rockville Pike
Bethesda, MD 20892
Phone+1 240-760-6092

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1981 - 1984
Stanford University School of MedicineClass of 1981

Certifications & Licensure

CA State Medical License 2019 - 2027
WV State Medical License 1985 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 1993 May 08
Completed
Phase 2
Treatment and Natural History Study of Lymphomatoid Granulomatosis Start of enrollment: 1995 May 05
Active, not recruiting
Phase 2
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Start of enrollment: 1997 Jan 08
Completed
Phase 2
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Start of enrollment: 1997 Sep 01
Completed
Phase 2
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma Start of enrollment: 2000 Jun 01
Completed
Phase 2
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection Start of enrollment: 2001 Jan 29
Active, not recruiting
Phase 2
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia Start of enrollment: 1999 Jul 01
Completed
Phase 1
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia Start of enrollment: 2001 Aug 15
Terminated
Phase 1
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2002 Feb 01
Completed
Phase 2
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2003 Feb 01
Completed
Phase 2
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Start of enrollment: 2003 Sep 19
Completed
Phase 2
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas Start of enrollment: 2004 Apr 05
Terminated
Phase 2
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Start of enrollment: 2005 Jun 15
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Phase I Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-cell Lymphomas Start of enrollment: 2008 Sep 01
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas Start of enrollment: 2009 Oct 22
Completed
Phase 2
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 2
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma Start of enrollment: 2011 Jul 15
Withdrawn
Phase 1, Phase 2
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Start of enrollment: 2009 Jan 13
Completed
Phase 1
Tissue Collection for Studies of Lymph Cancer Start of enrollment: 2012 Sep 21
Recruiting
Join now to see all

Publications & Presentations

PubMed

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.
Michele Ceribelli, Frances Anne Tosto, Xiaohu Zhang, Christopher J Melani, Mark Roschewski
Proceedings of the National Academy of Sciences of the United States of America. 2024-12-03
3 citations
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
Jaewoo Choi, Michele Ceribelli, James D Phelan, Björn Häupl, Da Wei Huang
Cancer Cell. 2024-05-13
10 citations
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients.
Andrea J Radtke, Ekaterina Postovalova, Arina Varlamova, Alexander Bagaev, Maria Sorokina
Cancer Cell. 2024-03-11

Journal Articles

End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...
Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica
A Multiprotein Supercomplex Controlling Oncogenic Signalling in Lymphoma
Maryknoll M Palisoc, Lisa M Rimsza, Stephen M Hewitt, Wyndham H Wilson, Matthias Holdhoff, Fayez Estephan, Nature

Abstracts/Posters

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCLNovember 4th, 2021
Global Trial Eliminates Drugs, Pivots to New OnesOctober 23rd, 2020
Cancer Researchers Cross over to COVID-19 Clinical TrialsOctober 20th, 2020
Join now to see all

Grant Support

Phase I And II Study Of BCL Family Inhibitors In LymphomaNational Cancer Institute2011
Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaNational Cancer Institute2010–2011
Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayNational Cancer Institute2010–2011
Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclNational Cancer Institute2010–2011
Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclNational Cancer Institute2010–2011
Lymphoma StudiesNational Cancer Institute2010–2011
BCR Signaling In ABC DlbclNational Cancer Institute2010–2011
Phase III Study Of Bcl-Family Inhibitors In LymphomaNational Cancer Institute2010
Lymphoma StudiesDivision Of Clinical Sciences - Nci2009
Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaDivision Of Basic Sciences - Nci2009
Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayDivision Of Basic Sciences - Nci2009
Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclDivision Of Basic Sciences - Nci2009
Phase I/II Study Of Bcl-Family Inhibitors In LymphomaDivision Of Basic Sciences - Nci2009
Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclDivision Of Basic Sciences - Nci2009
Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaNational Cancer Institute2007–2008
Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayNational Cancer Institute2007–2008
Phase III Study Of Bcl-Family Inhibitors In LymphomaNational Cancer Institute2007–2008
Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclNational Cancer Institute2007–2008
Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclNational Cancer Institute2007–2008
Lymphoma StudiesNational Cancer Institute2007–2008
Randomized Phase II Study Of Borteozmibepoch-R In MantleDivision Of Basic Sciences - Nci2006
Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayDivision Of Basic Sciences - Nci2006
Phase III Study Of Bcl-Family Inhibitors In LymphomaDivision Of Basic Sciences - Nci2006
Phase II Study Of Flavopiridol In Mantle Cell Lymphoma ADivision Of Basic Sciences - Nci2006
Phase I Study Of Bortezomib And Da-Epoch-R With MicroarrDivision Of Basic Sciences - Nci2006
Lymphoma StudiesDivision Of Clinical Sciences - Nci1996–2006

WyndhamHopkinsWilsonMD

Dr. Wilson is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.